ADR120S is acquiring a 71.5% stake in AthleteMed, a Tokyo-based sports rehabilitation clinic, to enhance its capabilities in non-cellular regenerative therapies.
Target Information
ADR120S, formerly known as Cytori Therapeutics, is expanding its medical operations by acquiring AthleteMed, a sports clinic based in Chiyoda, Tokyo. This clinic specializes in rehabilitation services specifically designed for athletes. The acquisition aims to enhance ADR120S's portfolio of cell therapy services and related research initiatives, particularly focused on the treatment of sports injuries and degenerative knee joint diseases.
With projected financials indicating annual revenues of ¥242 million, an operating profit of ¥1.52 million, and net assets totaling ¥461 million by the fiscal year ending February 2025, AthleteMed presents a compelling addition to ADR120S’s business structure. By integrating AthleteMed’s rehabilitation expertise, ADR120S anticipates accelerating its development and deployment of innovative non-cellular regenerative medical treatments.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in Japan
The healthcare industry in Japan, particularly in the realm of sports medicine and rehabilitation, is rapidly evolving. With an increasing focus on athletic performance and recovery, there has been a notable rise
Similar Deals
ADR120S
invested in
アスリートメッド
in 2026
in a Buyout deal
Disclosed details
Revenue: $2M
EBIT: $0M